6.82 USD
▲-0.03+6.73%
盘后 6.40 +0.16%
2026-08-03
市值
$388.71M
市盈率
7.46
EPS
0.91
股息率
—
52 周区间
4.00 – 7.54
成交量
1.22M
Beta
1.33
目标价
19.71
52W 低 4.0052W 高 7.54
价格走势
公司简介
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor...